deltatrials
Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 4-arm NCT04661007

To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) (J-MIND)

A Phase 1b/2 Study of Tafasitamab, Tafasitamab Plus Lenalidomide, Tafasitamab Plus Parsaclisib, and Tafasitamab Plus Lenalidomide in Combination With R-CHOP in Japanese Participants With Non-Hodgkin Lymphoma

Sponsor: Incyte Biosciences Japan GK

Updated 20 times since 2021 Last updated: Dec 16, 2025 Started: Dec 15, 2020 Primary completion: Dec 31, 2026 Completion: Dec 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Diffuse Large B-cell Lymphoma and Non Hodgkins Lymphoma and is currently ongoing. Incyte Biosciences Japan GK leads this study, which shows 20 recorded versions since 2020 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Sep 2021 · 6 months · monthly snapshot~Sep 2021 – ~Feb 2022 · 5 months · monthly snapshot~Feb 2022 – ~Jul 2022 · 5 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Aug 2023 · 8 months · monthly snapshot~Aug 2023 – ~Oct 2023 · 2 months · monthly snapshot~Oct 2023 – ~Mar 2024 · 5 months · monthly snapshot~Mar 2024 – ~May 2024 · 2 months · monthly snapshot~May 2024 – ~Jun 2024 · 31 days · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Jan 2025 · 31 days · monthly snapshot~Jan 2025 – ~Aug 2025 · 7 months · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – ~Jan 2026 · 4 months · monthly snapshot~Jan 2026 – present · 8 months · monthly snapshot

Change History

20 versions recorded
  1. Jan 2026 — Present [monthly]

    Active Not Recruiting PHASE1/PHASE2

  2. Sep 2025 — Jan 2026 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  3. Aug 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Status: RecruitingActive Not Recruiting

  4. Jan 2025 — Aug 2025 [monthly]

    Recruiting PHASE1/PHASE2

  5. Dec 2024 — Jan 2025 [monthly]

    Recruiting PHASE1/PHASE2

Show 15 earlier versions
  1. Sep 2024 — Dec 2024 [monthly]

    Recruiting PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2PHASE1/PHASE2

  3. Jun 2024 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

    Phase: PHASE1PHASE1_PHASE2

  4. May 2024 — Jun 2024 [monthly]

    Recruiting PHASE1

  5. Mar 2024 — May 2024 [monthly]

    Recruiting PHASE1

  6. Oct 2023 — Mar 2024 [monthly]

    Recruiting PHASE1

  7. Aug 2023 — Oct 2023 [monthly]

    Recruiting PHASE1

  8. Dec 2022 — Aug 2023 [monthly]

    Recruiting PHASE1

  9. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE1

  10. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE1

  11. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE1

  12. Feb 2022 — Jul 2022 [monthly]

    Recruiting PHASE1

  13. Sep 2021 — Feb 2022 [monthly]

    Recruiting PHASE1

  14. Mar 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

    Status: Not Yet RecruitingRecruiting

  15. Jan 2021 — Mar 2021 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Dec 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Incyte Biosciences Japan GK
Data source: Incyte Corporation

For direct contact, visit the study record on ClinicalTrials.gov .